Amneal Pharmaceuticals Inc (NYSE:AMRX) – Research analysts at SunTrust Banks lowered their Q3 2018 earnings estimates for Amneal Pharmaceuticals in a research report issued to clients and investors on Monday, October 15th. SunTrust Banks analyst J. Boris now anticipates that the company will post earnings per share of $0.27 for the quarter, down from their prior forecast of $0.29. SunTrust Banks has a “Hold” rating and a $15.00 price objective on the stock.
A number of other analysts have also recently weighed in on the company. Royal Bank of Canada upgraded Amneal Pharmaceuticals from a “sector perform” rating to an “outperform” rating in a research report on Monday, August 13th. Zacks Investment Research upgraded Amneal Pharmaceuticals from a “hold” rating to a “buy” rating and set a $21.00 price target on the stock in a research report on Saturday, July 14th. ValuEngine cut Amneal Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, September 27th. Morgan Stanley initiated coverage on Amneal Pharmaceuticals in a research report on Monday, July 23rd. They set an “overweight” rating and a $22.00 price target on the stock. Finally, Canaccord Genuity reiterated a “hold” rating and set a $21.00 price target on shares of Amneal Pharmaceuticals in a research report on Tuesday, September 4th. One investment analyst has rated the stock with a sell rating, six have given a hold rating and four have assigned a buy rating to the stock. The company has an average rating of “Hold” and an average price target of $22.75.
NYSE:AMRX opened at $18.51 on Thursday. The company has a debt-to-equity ratio of 2.85, a quick ratio of 1.25 and a current ratio of 2.01. Amneal Pharmaceuticals has a 52 week low of $13.47 and a 52 week high of $24.48. The company has a market cap of $6.62 billion, a price-to-earnings ratio of 29.41, a PEG ratio of 0.98 and a beta of 1.41.
Amneal Pharmaceuticals (NYSE:AMRX) last released its earnings results on Thursday, August 9th. The company reported $0.24 EPS for the quarter, topping analysts’ consensus estimates of $0.23 by $0.01. Amneal Pharmaceuticals had a negative return on equity of 8.74% and a negative net margin of 52.94%. The company had revenue of $462.33 million for the quarter, compared to the consensus estimate of $460.82 million. The company’s quarterly revenue was down 2.5% on a year-over-year basis.
In related news, SVP Nikita Shah sold 50,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 21st. The stock was sold at an average price of $23.46, for a total value of $1,173,000.00. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Bryan M. Reasons sold 11,698 shares of the firm’s stock in a transaction that occurred on Tuesday, August 21st. The shares were sold at an average price of $23.65, for a total value of $276,657.70. The disclosure for this sale can be found here. 3.20% of the stock is currently owned by corporate insiders.
A number of institutional investors and hedge funds have recently bought and sold shares of AMRX. Xact Kapitalforvaltning AB acquired a new stake in Amneal Pharmaceuticals in the 2nd quarter valued at approximately $203,000. Bank of Montreal Can acquired a new stake in Amneal Pharmaceuticals in the 2nd quarter valued at approximately $541,000. Scout Investments Inc. acquired a new stake in Amneal Pharmaceuticals in the 2nd quarter valued at approximately $1,752,000. Fox Run Management L.L.C. acquired a new stake in Amneal Pharmaceuticals in the 2nd quarter valued at approximately $228,000. Finally, Boston Advisors LLC acquired a new stake in Amneal Pharmaceuticals in the 2nd quarter valued at approximately $613,000. Hedge funds and other institutional investors own 32.41% of the company’s stock.
Amneal Pharmaceuticals Company Profile
Amneal Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, markets, and distributes generic pharmaceutical products for various dosage forms and therapeutic areas. It operates through Generic and Specialty Pharma divisions. The company's generics portfolio includes approximately 200 product families marketed in various dosage forms, such as solid oral doses comprising tablets, capsules, and powders; liquids; sterile injectables; nasal sprays; inhalation and respiratory products; ophthalmics; films; transdermal patches; and topicals, as well as soft gel, complex molecule, and drug-device combinations.
See Also: Outstanding Shares
Receive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.